IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

被引：2
|
作者：
French, Pim [1 ]
Erdem-Eraslan, L. [1 ]
Kros, J. M. [1 ]
Oosterkamp, H. M. [1 ]
Walenkamp, A. M. E. [1 ]
Beerepoot, L. [1 ]
Hanse, M. [1 ]
Buter, J. [1 ]
Honkoop, A. [1 ]
van der Holt, B. [1 ]
Vernhout, R. M. [1 ]
Smitt, P. A. E. Sillevis [1 ]
Taal, W. [1 ]
van den Bent, M. J. [1 ]
机构：
[1] Erasmus MC Canc Ctr, Rotterdam, Netherlands
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou206.29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [22] TOXICITY OF COMBINED BEVACIZUMAB-LOMUSTINE TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): REPORT FROM A RANDOMIZED PHASE II STUDY
    van den Bent, Martin
    Taal, Walter
    Sleijfer, Stefan
    van Heuvel, Irene
    SillevisSmitt, Peter A.
    Bromberg, Jacoline E.
    Vernhout, Irene
    NEURO-ONCOLOGY, 2010, 12 : 42 - 42
  • [23] A RETROSPECTIVE REVIEW OF PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) TREATED WITH BEVACIZUMAB (AVASTIN), LOMUSTINE (CCNU) AND SIROLIMUS (RAPAMUNE)
    Ranjan, Tulika
    Peters, Katherine
    Vlahovic, Gordana
    Friedman, Henry
    Desjardins, Annick
    NEURO-ONCOLOGY, 2013, 15 : 127 - 127
  • [24] A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414, BEVACIZUMAB (BEV) AND CCNU
    De Silva, Madhawa
    Lee, Adrian
    Kastela, Marina
    Wheeler, Helen
    Khasraw, Mustafa
    NEURO-ONCOLOGY, 2019, 21 : 19 - 19
  • [25] Cyclin El overexpression identifies patients with greater benefit from bevacizumab in platinum sensitive recurrent ovarian cancer
    Ribeiro, Adriana Regina G.
    Salvadori, Marcella M.
    de Brot, Louise
    Bovolim, Graziele
    Mantoan, Henrique
    Ilelis, Felipe
    Alves, Mariana R.
    Amaral, Nayra Soares
    Sanches, Solange M.
    Lisboa, Joyce
    dos Santos, Elizabeth S.
    Pereira, Ronaldo
    Castro, Fabricio S.
    Lima, Joao Paulo S.
    Guimaraes, Andrea P.
    Baiocchi, Glauco
    Da Costa, Alexandre Andre B.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] LIQUID BIOPSY DISTINGUISHES RECURRENT GBM FROM RADIATION NECROSIS IN PERIPHARAL BLOOD OF PATIENTS WITH GBM
    Soler, David
    Young, Andrew
    Cooper, Kevin
    McCormick, Thomas
    Sloan, Andrew
    NEURO-ONCOLOGY, 2016, 18 : 178 - 178
  • [27] LIQUID BIOPSY DISTINGUISHES RECURRENT GBM FROM RADIATION NECROSIS IN PERIPHARAL BLOOD OF PATIENTS WITH GBM
    Soler, David C.
    Young, Anrew B.
    Cooper, Kevin D.
    Kerstetter-Fogle, Amber
    Barnholtz-Sloan, Jill S.
    Gittleman, Haley
    McCormick, Thomas S.
    Sloan, Andrew E.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (04) : 813 - 813
  • [28] RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
    Gilbert, M. R.
    Wang, M.
    Aldape, K.
    Lassman, A.
    Sorensen, A. G.
    Mikkelson, T.
    Groves, M.
    Werner-Wasik, M.
    Regine, W.
    Mehta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Radiographic pattern of progression of recurrent GBM treated with bevacizumab with or without irinotecan.
    Dory-Lautrec, P.
    Tabouret, E.
    Barrie, M.
    Boucard, C.
    Matta, M.
    Autran, D.
    Girard, N.
    Chinot, O. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM)
    Lassman, A. B.
    Iwamoto, F. M.
    Gutin, P. H.
    Abrey, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345